Anthrax
Elusys Therapeutics completes human clinical study of the anthrax therapeutic Anthim
Published in Medical Letter on the CDC and FDA, April 26th, 2006
The Phase I study was designed to determine the safety and tolerability of Anthim in healthy volunteers, when administered with or without the antibiotic Ciprofloxacin.
The principal investigator for this study, Glen Apseloff, MD, Division of Clinical Pharmacology at The Ohio State University Clinical Pharmacology Unit commented, "The Anthim Phase 1 study, AH-101, has concluded and all subjects have completed the 42 day study. There were no serious adverse events and the drug was well tolerated,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Carcinogenesis
Acrylamide and its metabolite glycidamide are genotoxic in mice - Polymerase Chain Reaction
PCR method to detect toxin genes in enterotoxigenic Escherichia coli has been developed - Salmonellosis
Drug-resistant Salmonella outbreak is linked to ground beef in U.S. - Salmonellosis
Sample preparation affects recovery of Salmonella from fruit - Acne
Reliant Technologies announces U.S. FDA clearance of the Fraxel Laser for acne and surgical scars - Adverse Drug Reaction
Fosphenytoin may cause hemodynamically unstable bradydysrhythmias - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
